Abstract

The BRMP is interested in the extramural clinical evaluation of monoclonal antibodies, and intends to turn its attentionto the area of immunoconjugates. A number of Phase I clinical trials have been carried out using several monoclonal antibodies in human malignancies. The BRMP intends to support a limited number of Phase I/II trials utilizing T101 and another monoclonal antibody against a solid tumor, conjugated with either radioisotopes, doxorubicin, or vindesine.

  Funding Agency

Agency
National Institute of Health (NIH)
Institute
Division of Cancer Treatment (NCI)
Type
Research and Development Contracts (N01)
Project #
N01CM047667-002005
Application #
3612114
Study Section
Project Start
1984-09-29
Project End
Budget Start
1986-08-22
Budget End
1986-12-31
Support Year
Fiscal Year
1986
Total Cost
Indirect Cost

  Institution

Name
Illinois Cancer Center
Department
Type
DUNS #
City
Chicago
State
IL
Country
United States
Zip Code
60604

  Publications

Dykewicz, M S; Rosen, S T; O'Connell, M M et al. (1992) Plasma histamine but not anaphylatoxin levels correlate with generalized urticaria from infusions of anti-lymphocyte monoclonal antibodies. J Lab Clin Med 120:290-6
Dykewicz, M S; Cranberg, J A; Patterson, R et al. (1990) Human IgE, IgG and IgA antibody responses to T101, a murine monoclonal antibody against human lymphocytes: implications for pathogenesis, risk and avoidance of adverse immunologic reactions. Int Arch Allergy Appl Immunol 92:131-7
Sosman, J A; Hank, J A; Sondel, P M (1990) In vivo activation of lymphokine-activated killer activity with interleukin-2: prospects for combination therapies. Semin Oncol 17:22-30;discussion 38-41
Creekmore, S P; Harris, J E; Ellis, T M et al. (1989) A phase I clinical trial of recombinant interleukin-2 by periodic 24-hour intravenous infusions. J Clin Oncol 7:276-84
Rosen, S T; Zimmer, A M; Goldman-Leikin, R et al. (1989) Progress in the treatment of cutaneous T cell lymphomas with radiolabeled monoclonal antibodies. Int J Rad Appl Instrum B 16:667-8
Ellis, T M; Creekmore, S P; McMannis, J D et al. (1988) Appearance and phenotypic characterization of circulating Leu 19+ cells in cancer patients receiving recombinant interleukin 2. Cancer Res 48:6597-602
Goldman-Leikin, R E; Kaplan, E H; Zimmer, A M et al. (1988) Long-term persistence of human anti-murine antibody responses following radioimmunodetection and radioimmunotherapy of cutaneous T-cell lymphoma patients using 131I-T101. Exp Hematol 16:861-4
Rosen, S T; Zimmer, A M; Goldman-Leikin, R et al. (1987) Radioimmunodetection and radioimmunotherapy of cutaneous T cell lymphomas using an 131I-labeled monoclonal antibody: an Illinois Cancer Council Study. J Clin Oncol 5:562-73